Evaluation of Silibinin Effects on the Viability of HepG2 (Human Hepatocellular Liver Carcinoma) and HUVEC (Human Umbilical Vein Endothelial) Cell Lines

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2018 May 15

PMID 29755557

Citations 11

Authors

Niki Vakili Zahir

Maryam Nakhjavani

Parastoo Hajian

Farshad H Shirazi

Hamidreza Mirzaei

Affiliations

Soon will be listed here.

Abstract

Human hepatocellular carcinoma is one of the most common recurrent malignancies since there is no effective therapy for it. Silibinin, a widely used drug and supplement for various liver disorders, demonstrated anti-cancer effects on human hepatocellular carcinoma, human prostate adenocarcinoma cells, human breast carcinoma cells, human ectocervical carcinoma cells, and human colon cancer cells. Considering the anti-hepatotoxic activity of silibinin and its strong preventive and anti-cancer efficacy against various epithelial cancers, we investigated the efficacy of silibinin against human HCC and HUVEC cell lines. Silibinin effects on the growth and mode of cell death of these two cell lines are presented in this paper. HepG2 and HUVEC cells were incubated with different doses of silibinin (12.5, 25, 50, 100, 150 and 200 μg/mL) at 24, 48, and 72 h. Cytotoxicity was assessed using MTT and Trypan blue assays. Mode of cell death induced by silibinin was investigated using LDH assay and acridine orange/PI double dye staining. The results showed that silibinin has dose-dependent inhibitory effect on the viability of HepG2 and HUVEC cells. However, Silibinin causes a more continuous dose-dependent cytotoxicity in HepG2 cells compared to the HUVEC cells in which some degrees of resistance is apparent at the beginning. The mode of cell death looks also different in these two cell lines with HepG2 cells being more in favor of apoptosis while necrosis is more evident for the HUVEC cells.

Citing Articles

Novel Strategies Enhancing Bioavailability and Therapeutical Potential of Silibinin for Treatment of Liver Disorders.

Selc M, Macova R, Babelova A Drug Des Devel Ther. 2024; 18:4629-4659.

PMID: 39444787 PMC: 11498047. DOI: 10.2147/DDDT.S483140.

A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment.

Ray P, Islam M, Islam M, Han A, Geng P, Aziz M Front Pharmacol. 2024; 15:1349745.

PMID: 38487172 PMC: 10937417. DOI: 10.3389/fphar.2024.1349745.

A New Glucosyl Flavone with Inhibitory Activity of Cancer Cell Viability and Other Bioactive Constituents from the Traditional Kurdish Plant L.

Amin H, Amin K, Armijos C, Hussain F, Jawhar Z, Caprioglio D Molecules. 2024; 29(5).

PMID: 38474591 PMC: 10933755. DOI: 10.3390/molecules29051079.

Cytotoxicity of Reproductive Stage Leaf and Stem on HepG2 Cell Line.

Lingfa L, Tirumala A, Ankanagari S Evid Based Complement Alternat Med. 2024; 2023:8832166.

PMID: 38169931 PMC: 10761218. DOI: 10.1155/2023/8832166.

Diallyl Disulfide Induces Chemosensitization to Sorafenib, Autophagy, and Cell Cycle Arrest and Inhibits Invasion in Hepatocellular Carcinoma.

Machado A, Tuttis K, Santos P, Aissa A, Antunes L Pharmaceutics. 2022; 14(12).

PMID: 36559076 PMC: 9788602. DOI: 10.3390/pharmaceutics14122582.

References

Agarwal R . Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 2000; 60(8):1051-9. DOI: 10.1016/s0006-2952(00)00385-3. View

Singh R, Tyagi A, Zhao J, Agarwal R . Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis. 2002; 23(3):499-510. DOI: 10.1093/carcin/23.3.499. View

Bhatia N, Zhao J, Wolf D, Agarwal R . Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett. 2000; 147(1-2):77-84. DOI: 10.1016/s0304-3835(99)00276-1. View

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

Yousefi M, Ghaffari S, Zekri A, Hassani S, Alimoghaddam K, Ghavamzadeh A . Silibinin induces apoptosis and inhibits proliferation of estrogen receptor (ER)-negative breast carcinoma cells through suppression of nuclear factor kappa B activation. Arch Iran Med. 2014; 17(5):366-71. DOI: 0141705/AIM.0011. View

Singh R, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R . Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev. 2003; 12(9):933-9. View

Hu K, Yu C, Mineyama Y, McCracken J, Hillebrand D, Hasan M . Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. Int J Oncol. 2003; 22(4):757-63. View

Saller R, Meier R, Brignoli R . The use of silymarin in the treatment of liver diseases. Drugs. 2001; 61(14):2035-63. DOI: 10.2165/00003495-200161140-00003. View

Kroll D, Shaw H, Oberlies N . Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007; 6(2):110-9. DOI: 10.1177/1534735407301825. View

10.

Kelloff G, Lieberman R, Steele V, Boone C, Lubet R, Kopelovitch L . Chemoprevention of prostate cancer: concepts and strategies. Eur Urol. 1999; 35(5-6):342-50. DOI: 10.1159/000019906. View

11.

Katiyar S, Mohan R, Agarwal R . A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999; 59(3):622-32. View

12.

Pepping J . Milk thistle: Silybum marianum. Am J Health Syst Pharm. 1999; 56(12):1195-7. DOI: 10.1093/ajhp/56.12.1195. View

13.

Mazaki M, Ishii T, Uyeta M . Mutagenicity of hydrolysates of citrus fruit juices. Mutat Res. 1982; 101(4):283-91. DOI: 10.1016/0165-1218(82)90121-5. View

14.

Tyagi A, Agarwal C, Harrison G, Glode L, Agarwal R . Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004; 25(9):1711-20. DOI: 10.1093/carcin/bgh180. View

15.

Mohan S, Dhanalakshmi S, Mallikarjuna G, Singh R, Agarwal R . Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun. 2004; 320(1):183-9. DOI: 10.1016/j.bbrc.2004.05.153. View

16.

Singh R, Dhanalakshmi S, Agarwal C, Agarwal R . Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene. 2004; 24(7):1188-202. DOI: 10.1038/sj.onc.1208276. View

17.

Chu S, Chiou H, Chen P, Yang S, Hsieh Y . Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 2004; 40(3):143-9. DOI: 10.1002/mc.20018. View

18.

Varghese L, Agarwal C, Tyagi A, Singh R, Agarwal R . Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res. 2005; 11(23):8441-8. DOI: 10.1158/1078-0432.CCR-05-1646. View

19.

Gazak R, Walterova D, Kren V . Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem. 2007; 14(3):315-38. DOI: 10.2174/092986707779941159. View

20.

Cui W, Yu C, Hu K . In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res. 2005; 11(22):8213-21. DOI: 10.1158/1078-0432.CCR-05-1044. View